Compare Gold Fields Limited (GFI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Gold Fields Limited is far larger — about 3.2× State Street SPDR S&P Biotech ETF's market cap, and Gold Fields Limited pays a 6% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GFI | XBI | |
|---|---|---|
Market Cap | $31.87B | $10.11B |
Volume | 4,169,651 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $61.52 | $169.55 |
52-Week Low | $31.25 | $104.99 |
Typical Hold Time | 49 Days | 38 Days |
Enterprise Value | $32.47B | — |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal and mixed earnings history. The stock shows strong fundamentals with a P/E of 7.3, net income margin of 38.66%, and robust cash flow growth, while recent news highlights a rejected $27 billion takeover bid for Northern Star, creating investor uncertainty.
The outlook is balanced: valuation metrics and profitability support upside toward the $52.75 analyst target, but near-term risks include acquisition-related volatility and technical weakness. Investors should weigh high ROE and cash returns against execution risks from expansion efforts.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
